Jazz Pharmaceuticals plc (JAZZ) Financials

JAZZ Assets vs Liabilities

DateAssetsLiabilities
June 30, 2026 11.1 billion 6.3 billion
March 31, 2026 11.9 billion 7.3 billion
Dec. 31, 2025 11.7 billion 7.3 billion
Sept. 30, 2025 11.4 billion 7.4 billion

JAZZ Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 397.6 million 73.3 million
March 31, 2026 388.5 million 74.5 million
Dec. 31, 2025 296.8 million 199.8 million
Sept. 30, 2025 459.4 million 88.1 million

JAZZ Net Income

Graph available only for paid members. Upgrade to see it.
DateNet Income
June 30, 2026 192.8 million
March 31, 2026 293.1 million
Dec. 31, 2025 -903.6 million
Sept. 30, 2025 251.4 million

JAZZ Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 2.2 billion 3.3 billion 43.6 million
March 31, 2026 2.9 billion 4.3 billion 62.2 million
Dec. 31, 2025 2.4 billion 4.3 billion 65.6 million
Sept. 30, 2025 2.0 billion 4.3 billion 53.4 million

JAZZ Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 69.4 million
March 31, 2026 66.1 million
Dec. 31, 2025 61.0 million
Sept. 30, 2025 61.6 million

JAZZ Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 18.1 million 207.5 million 389.2 million -
March 31, 2026 19.7 million 134.1 million 352.7 million -
Dec. 31, 2025 65.7 million 171.4 million 406.2 million -
Sept. 30, 2025 15.2 million 240.7 million 530.6 million -

JAZZ Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 1.2 billion 116.4 million
March 31, 2026 1.1 billion 306.4 million
Dec. 31, 2025 1.2 billion 24.6 million
Sept. 30, 2025 1.1 billion 257.8 million

JAZZ Revenue by Segment

Graph available only for paid members. Upgrade to see it.

JAZZ

Price: $246.81

52 week price:
109.87
265.05

Payout Ratio Range:
22.18%
119.25%

Earnings Per Share: 14.62 USD

P/E Ratio: 17.55

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: Ireland

Volume: 468012

Ebitda: 136.8 million

Market Capitalization: 16.7 billion

Links: